NASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis $29.96 -0.34 (-1.12%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$29.96 +0.00 (+0.02%) As of 08/29/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RARE alerts:Sign Up Key Stats Today's Range$29.71▼$30.6050-Day Range$26.31▼$41.4452-Week Range$25.81▼$60.37Volume1.34 million shsAverage Volume1.47 million shsMarket Capitalization$2.89 billionP/E RatioN/ADividend YieldN/APrice Target$81.50Consensus RatingModerate Buy Company Overview Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval. The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders. These products illustrate Ultragenyx’s approach of targeting well-defined genetic defects with therapies designed to correct or mitigate the underlying cause of disease. Ultragenyx maintains a robust clinical pipeline, with investigational treatments in various stages of development for conditions such as congenital hyperinsulinism, pyruvate kinase deficiency and other rare enzymatic or metabolic disorders. Ultragenyx operates globally, with a commercial presence in the United States, Europe and Canada, and research collaborations spanning multiple continents. The company works closely with patient advocacy groups and academic centers to support clinical trials and foster patient access. Under the leadership of founder and Chief Executive Officer Emil Kakkis—an experienced clinician-scientist in the rare disease field—Ultragenyx continues to expand its capabilities in manufacturing, regulatory affairs and global commercialization to deliver transformative therapies for underserved patient populations.AI Generated. May Contain Errors. Read More Ultragenyx Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreRARE MarketRank™: Ultragenyx Pharmaceutical scored higher than 94% of companies evaluated by MarketBeat, and ranked 89th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ultragenyx Pharmaceutical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($5.18) to ($3.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -5.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -5.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 10.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ultragenyx Pharmaceutical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.39% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently decreased by 13.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-2.28 Percentage of Shares Shorted8.39% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently decreased by 13.18%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.28 News SentimentUltragenyx Pharmaceutical has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.12 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Ultragenyx Pharmaceutical this week, compared to 10 articles on an average week.Search InterestOnly 8 people have searched for RARE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows16 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $89,923.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ultragenyx Pharmaceutical's insider trading history. Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RARE Stock News HeadlinesUltragenyx to Participate at Investor Conferences in SeptemberAugust 29, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREAugust 29, 2025 | globenewswire.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning. | InvestorPlace (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREAugust 27, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREAugust 25, 2025 | globenewswire.comUltragenyx Pharmaceutical (RARE) Valuation Spotlight as DTX401 Gene Therapy Advances With FDA SubmissionAugust 24, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREAugust 22, 2025 | prnewswire.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 21, 2025 | globenewswire.comSee More Headlines RARE Stock Analysis - Frequently Asked Questions How have RARE shares performed this year? Ultragenyx Pharmaceutical's stock was trading at $42.07 at the beginning of 2025. Since then, RARE shares have decreased by 28.8% and is now trading at $29.96. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its quarterly earnings results on Tuesday, August, 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.10. The business's revenue was up 13.2% compared to the same quarter last year. Read the conference call transcript. Who are Ultragenyx Pharmaceutical's major shareholders? Top institutional investors of Ultragenyx Pharmaceutical include Sands Capital Management LLC (4.09%), State Street Corp (2.67%), Federated Hermes Inc. (2.13%) and Geode Capital Management LLC (1.81%). Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, John Richard Pinion, Howard Horn, Dennis Karl Huang, Eric Crombez, Mardi Dier, Karah Herdman Parschauer, Erik Harris, Theodore Alan Huizenga, Camille L Bedrosian, Corazon (Corsee) D Sanders and Matthew K Fust. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/05/2025Today9/01/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RARE CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,310Year Founded2010Price Target and Rating Average Price Target for Ultragenyx Pharmaceutical$81.50 High Price Target$128.00 Low Price Target$34.00 Potential Upside/Downside+172.0%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($5.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$569.18 million Net Margins-87.34% Pretax Margin-86.93% Return on Equity-237.48% Return on Assets-37.66% Debt Debt-to-Equity RatioN/A Current Ratio2.45 Quick Ratio2.30 Sales & Book Value Annual Sales$560.23 million Price / Sales5.15 Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book10.86Miscellaneous Outstanding Shares96,370,000Free Float91,072,000Market Cap$2.89 billion OptionableOptionable Beta0.21 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:RARE) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.